Accuracy of the New Barrett TAL Formula With the Argos Measurements: A Multicenter Prospective Study

Sponsor
Shammas Eye Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT06085131
Collaborator
Sengi (Industry)
590
6
11.2
98.3
8.8

Study Details

Study Description

Brief Summary

This study is a prospective, multi-site, multi-surgeon, observational study of refractive accuracy with the Argos using BTAL after successful cataract surgery. Subjects will be assessed pre-operatively, operatively and at 5-8 weeks postoperatively. Clinical evaluations will include measurement of visual acuity, manifest refraction, and preoperative biometry.

Condition or Disease Intervention/Treatment Phase
  • Device: Argos

Study Design

Study Type:
Observational
Anticipated Enrollment :
590 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Accuracy of the New Barrett TAL Formula With the Argos Measurements: A Multicenter Prospective Study
Anticipated Study Start Date :
Oct 24, 2023
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Argos Biometer

Preoperative biometry with the Argos device

Device: Argos
Argos Biometer

Outcome Measures

Primary Outcome Measures

  1. The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction ≤ ±0.50 D. [2 months postoperative]

Secondary Outcome Measures

  1. The percentage of eyes that achieve a postoperative manifest spherical equivalent refraction ≤ ±0.250D, ≤ ±0.75D and ≤ ±1.00D. [2 months postoperative]

  2. The Mean Predictive Error and its standard deviation after constant personalization for the entire series. [2 months postoperative]

  3. The Mean Predictive Errors in the short eyes and in the long eyes [2 months postoperative]

    The Mean Predictive Errors in the short eyes and in the long eyes (Short AL<22.5mm, Long AL >24.5mm and Medium AL 22.6mm to 24.4mm), and the percentage of eyes that achieve a postoperative manifest spherical equivalent refraction ≤ ±0.25 D, ≤ ±0.50 D, ≤ ±0.75 D and ≤ ±1.00 D in each of these categories.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Subjects are eligible for the study if they meet the following criteria:
  • Cataract surgery that was completed without complications with biometry measured using the Argos biometer.

  • Subjects that elect Clareon SY60WF aspheric lens (Alcon, Fort Worth, TX).

  • Potential post-operative visual acuity of better than logMAR 0.30 (20/40).

  • BTAL was used to determine the IOL power implanted.

Exclusion Criteria:

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Patients with pre-existing ocular pathology that in the opinion of the principial investigator would influence the postoperative refraction.

  • Any disease or pathology, including but not limited to irregular corneal astigmatism and keratoconus, that is expected to reduce the potential postoperative BCDVA to a level worse than 20/40.

  • Patients with history of previous ocular surgery.

  • Patients with signs of inability to understand consent for study and procedure planned.

  • Eyes with intraoperative or postoperative complications.

  • Suboptimal surgical outcomes that are not related to the treatment plan, e.g. capsular tear, cystoid macular edema.

  • Astigmatism >±0.75D.

Each investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Colvard-Kandavel Eye Center Encino California United States 91316
2 Shammas Eye Medical Center Lynwood California United States 90262
3 Shammas Eye Center Whittier California United States 90602
4 Multack Eye Care, Sc Frankfort Illinois United States 60461
5 Multack Eye Care, SC Olympia Fields Illinois United States 60461
6 Juliette Eye Institute Albuquerque New Mexico United States 87113

Sponsors and Collaborators

  • Shammas Eye Medical Center
  • Sengi

Investigators

  • Principal Investigator: H J Shammas, MD, Shammes Eye Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shammas Eye Medical Center
ClinicalTrials.gov Identifier:
NCT06085131
Other Study ID Numbers:
  • HJS-23-01
First Posted:
Oct 16, 2023
Last Update Posted:
Oct 16, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 16, 2023